** Fulcrum Therapeutics' FULC.O shares fall 3% to $3.27 after the bell

** FULC approves restructuring plan after discontinuing pociredir for sickle-cell disease

** Fulcrum abandoned development of the drug following cancer-risk concerns raised by the U.S. FDA

** Co to trim its workforce by 85%, from 57 to 9 employees, to be completed by Q2

** Expects restructuring charges of about $4.2 mln to be incurred in Q2

** FULC down 70% YTD